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Abstract
Aims: To determine the incidence of congenital toxoplasmosis in Colombian newborns from 19 hospital or maternal child
health services from seven different cities of five natural geographic regions (Caribbean, Central, Andean, Amazonia and
Eastern).
Materials and Methods: We collected 15,333 samples from umbilical cord blood between the period of March 2009 to May
2010 in 19 different hospitals and maternal-child health services from seven different cities. We applied an IgM ELISA assay
(Vircell, Spain) to determine the frequency of IgM anti Toxoplasma. The results in blood cord samples were confirmed either
by western blot and repeated ELISA IgM assay. In a sub-sample of 1,613 children that were negative by the anti-Toxoplasma
IgM assay, the frequency of specific anti-Toxoplasma IgA by the ISAGA assay was determined. All children with positive
samples by IgM, IgA, clinical diagnosis or treatment during pregnancy were recalled for confirmatory tests after day 10 of
life.
Results: 61 positive samples for specific IgM (0.39%) and 9 positives for IgA (0.5%) were found. 143 questionnaires were
positive for a clinical diagnosis or treatment for toxoplasmosis during pregnancy. 109 out of the 218 children that had some
of the criteria for postnatal confirmatory tests were followed. Congenital toxoplasmosis infection was confirmed in 15
children: 7 were symptomatic, and three of them died before the first month of life (20% of lethality). A significant
correlation was found between a high incidence of markers for congenital toxoplasmosis and higher mean annual rainfall
for the city.
Conclusions: Incidence for congenital toxoplasmosis is significantly different between hospitals or maternal child health
services from different cities in Colombia. Mean annual rainfall was correlated with incidence of congenital toxoplasmosis.
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Introduction
Congenital toxoplasmosis is generally the result of a primary
infection during pregnancy. The clinical manifestation of the
infant will depend of the gestational week when the mother
acquired the infection and is characterized by a broad spectrum of
symptoms at birth, including varying degrees of neurologic,
ophthalmologic and systemic involvement [1]. Recent reports
indicate that congenital toxoplasmosis is more often symptomatic
in South America than in Europe. This was demonstrated when
cohorts of congenitally infected children from different continents
were compared [2]. The greater severity of South American cases
was an unexpected result of the SYROCOT international
collaborative study [2]. Additionally, a comparative prospective
www.plosntds.org 1 May 2011 | Volume 5 | Issue 5 | e1195cohort study of congenitally infected children in Brazil and Europe
found that Brazilian children had eye lesions that were larger,
more numerous, and more likely to affect the part of the retina
responsible for central vision, compared with their counterparts in
Europe [3]. The authors of the study suggested that the increased
frequency and severity of ocular disease in Brazil compared with
Europe was due to exposure to more virulent strains of Toxoplasma
gondii in Brazil [3]. Importantly, the parasite genotyping studies
indicated that current markers are not useful to indicate clinical
outcome, but they clearly showed a different parasite population
between Europe and South America [4].
There is a lack of epidemiological information about the
frequency and clinical characteristics of the congenital infection in
Colombia. In a literature survey only one study concerning
pregnant women was found in a Pubmed search [5]. An additional
search in non-indexed literature found 10 studies of prevalence in
general population and in pregnant women from some regions of
Colombia [5]. One of these studies was done in 1980 and it was
representative of the general population of the country. This
national screening survey determined 47% of prevalence of
specific anti- Toxoplasma IgG in general population, indicating a
high exposure to the parasite [6]. In the Quindio region a
frequency of 0.6% of congenital toxoplasmosis [7,8] and a higher
frequency of ocular involvement in 36% of congenitally infected
children has also been reported [9]. No information is reported in
other regions of the country for congenital toxoplasmosis. Actually,
there are no official control programs, despite a national guide for
congenital toxoplasmosis supported by the Colombian Association
of Infectious Diseases [5]. The perception of Colombian
pediatricians is that only few symptomatic congenital cases are
treated. Evidence of this situation was found in one survey in Cali
(a city in the pacific region of Colombia) where toxoplasmosis was
the second commonest cause of congenital blindness [10].
The neonatal detection of congenital toxoplasmosis was first
evaluated in the region of New England in the United States [11]
then in Denmark [12,13], Poland [14], Brazil [15–18] and more
recently in Colombia [7,8]. Incidence rates varied from a low
prevalence of 0.021% in Denmark to 0.6% live-newborn in
Quindio region in Colombia. In Brazil, a large country
characterized by heterogeneous socio-economic conditions and
cultural and hygiene-nutritional habits, studies in newborns have
reported heterogeneity in the incidence, ranging from 0.03 to
0.5% [15–18]. However, there have been few investigations in
other South American countries that define the real magnitude of
the problem. In previous investigations, confirmation of the
disease was obtained by the detection of anti- Toxoplasma IgM
antibodies in the newborn. Although this detection has been used
for definitive diagnosis [11,12] its use generally requires perform-
ing confirmatory testing. A definitive diagnosis would also be
possible by the direct detection of the parasite in clinical samples,
by demonstrating the persistence of anti-Toxoplasma IgG antibodies
beyond 1 year of age [17] and/or by the detection of anti-
Toxoplasma IgA in the first 6 months of life [14].
Considering the lack of information regarding the incidence of
congenital toxoplasmosis in Colombia, we proposed a multicentric
national study. The aim of this work was to determine the
incidence of congenital toxoplasmosis in Colombian newborns
from hospital and maternal child health services from seven
different cities in five natural geographic regions (Caribbean,
Central, Andean, Amazonia and the Eastern regions). The
confirmatory criteria used were the persistence of anti-Toxoplasma
IgG antibodies beyond 1 year of age or the presence of specific
anti-Toxoplasma IgM or IgA after the 10
th day of life. In addition,
clinical and laboratory findings for the identified infants are
described.
Methods
Ethical aspects
Informed written consent, according to the regulation 008430 of
1993 of the Ministry of Health of Colombia, was obtained from all
people that accepted to participate in the study. The University of
Quindio Institutional Review Board (act number 14, 23 June
2009) approved the study. Considerations in performing this study
were that obtaining umbilical cord blood samples was a non-risk
procedure, the study provided an additional use for a sample that
would otherwise be discarded, and that identifying infection would
benefit the infected child.
Selection of the sample and characteristics of the health
institutions participating in the multicentric study
In Colombia, according to 2003–2008 UNICEF statistics and
DANE (national statistics governmental institute) official reports,
92% of births occur in health institutions [19]. As part of the
screening for congenital hypothyroidism, umbilical cord blood
samples are taken routinely in most of regions in Colombia [20].
No other neonatal screening is performed in Colombia, excepting
the search for syphilis when the mother did not have screening
during pregnancy. Invitations for institutions to participate were
provided during the national congress of gynecology in 2008. The
only condition for participation was that the institutions which
agreed to participate would instruct the personnel at the delivery
room and would give information about the study to the parents.
The project covered the costs of screening assays and of the
laboratory assays needed for the follow up of the children. The 19
institutions that agreed to participate are listed in the Table 1, and
they were from the first to the third level of referral (first level is the
institution with simplest or basic level of health care and the third
level is the health institution for more complex and specialized
attention). Each institution was given a time to collect samples in a
consecutive manner, and a limited number of samples by city was
established. Collection of samples was stopped when the number
Author Summary
Congenital toxoplasmosis can result in permanent sequel
as blindness or neurological damage in children and it
seems to be more severe in South America than in other
continents. There is a lack of information about this
frequency in Colombia, where no control program is
established, although it is a recognized cause of potentially
preventable congenital blindness. We propose the first
Colombian multicentric study to determine the frequency
and impact of congenital toxoplasmosis. More than 15,000
newborns in seven cities were studied. Newborns were
tested at birth by doing a cord blood test for toxoplas-
mosis. Additionally, children from mothers with history of
toxoplasmosis acquired during pregnancy were recalled
for a follow-up. The program identified fifteen children
otherwise undiagnosed; three of these children died as
consequence of congenital toxoplasmosis. The frequency
of the congenital infection varied significantly between
cities, being higher in Armenia and Florencia, intermediate
in Bogota, Bucaramanga and Barranquilla and very low in
western cities such as Cucuta and Riohacha. For the first
time a significant correlation was found between mean
rainfall at the city and the incidence of this congenital
infection.
Colombian Newborn Screening for Toxoplasmosis
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to be collected in each city was: Barranquilla 3,000; Riohacha 800;
Bucaramanga 3,000; Cucuta 1,000; Bogota ´ 5,200; Florencia 500;
Armenia 1,500.
Questionnaire and flowchart for umbilical cord blood
samples
A questionnaire was required for all mothers, interrogating
about age, positive IgM anti-Toxoplasma test or treatment for
toxoplasmosis during pregnancy and SISBEN level. In Colombia,
socioeconomic level of the population is determined according to
the SISBEN classification, a socio-economic index [21]. The
SISBEN gives an approximated measure of the magnitude of
poverty, as an approximate indicator of resources or income, or as
an evaluation of fulfillment of needs [21].
If mother accepted to participate in the study, blood samples
from umbilical cord were collected at the moment of delivery. The
personnel at the hospital’s laboratory centrifuged and stored for a
maximum period of 8 days at 4uC in tubes and sent to the regional
laboratory.
ELISA IgM assay
Serum from the umbilical cord blood was analyzed for anti-
Toxoplasma IgM by a commercially available, enzyme immuno-
capture assay (Toxoplasma gondii IgM, Vircell, Grenade, Spain)
according to the manufacturer’s instructions. The absorbancies
were measured in a microplate reader at 450 nm, with reference
filter at 630 nm. Cutoff was calculated from western blot anti-
Toxoplasma IgM negative and anti-Toxoplasma IgG negative
samples. A receptor operating curve with 12 serums from
confirmed cases (including symptomatic and asymptomatic cases)
and 93 negative confirmed cases, indicated that a cutoff of index 8
detected all anti-Toxoplasma IgM positive cases in umbilical cord
blood samples. To control for run-to-run variations, results were
expressed as index, calculated by using the formula based on
optical density (OD) of samples and controls: OD sample/mean
OD of negative controls. The personnel at the regional
laboratories received the same training to perform the technique
under the same parameters. All positive samples were retested at
the national reference laboratory (‘‘Centro de Investigaciones
Biomedicas’’, Universidad del Quindio) again by the same ELISA
assay (Vircell), a Labsystems anti-Toxoplasma IgM assay (Helsinki,
Finland) and a western blot anti-Toxoplasma IgM test (LDbio,
France).
Additional criteria selection for confirmatory studies:
studies for anti-Toxoplasma IgA and past history of
diagnosis or treatment for toxoplasmosis during
pregnancy
Up to 20% of infants with congenital toxoplasmosis may have
negative anti-Toxoplasma IgM at birth [22]. Some reports
established that up to half of congenitally infected cases could
have anti-Toxoplasma IgA antibodies and that this immunoglobulin
can be found in absence of specific IgM [22,23]. It is not known if
there are geographical variations about the presence of the specific
IgA in absence of anti-Toxoplasma IgM. As an ELISA IgA was not
commercially available in Colombia, we decided to use a more
expensive test, the immunosorbent agglutination assay or ISAGA
(Biomerieux, Lyon, France), a reference immunocapture test that
use a formolized entire Toxoplasma antigen. Due to cost reasons, we
perform the assay for anti-Toxoplasma IgA in a subsample of 1,613
cord blood samples that were negative in the ELISA anti-
Toxoplasma IgM assay. Monthly, 10% of the first consecutive
negative samples, from each regional laboratory, were referred to
Table 1. Births and sample for newborn screening and referral level of participating centers.
City
Hospitals or maternal-child
health care center Referral level
Births 2009 at the
hospital or center
Sample (% total
births at the
hospital or center)
Armenia (Andean) 1. Hospital Universitario San Juan de Dios III 3,959 753 9%)
2. Hospital La Misericordia II 1,262 614 8%)
3. Hospital del Sur I 418 196 (46,8%)
Barranquilla (Caribbean) 4. Hospital Universidad del Norte III 1,164 1,043 (89%)
5. Hospital Santa Mo ´nica II 2,505 688 (27%)
6. Hospital Nin ˜oJ e ´sus II 2,702 1,170 (43%)
Bogota (Center) 7. Clı ´nica Colombia III 4,714 544 1.5%)
8. Hospital de Engativa ´ II 2,730 1,971 (72.2%)
9. Hospital La Victoria III 3,913 301 .6%)
10. Hospital Simo ´n Bolı ´var III 1,771 545 0.7%)
11. Instituto Materno Infantil III 3,026 2,037 (67.3%)
Bucaramanga (Eastern) 12. Hospital de Floridablanca II 1,700 981 7.7%)
13. UIMIST I 1,181 659 5.8%)
14. Los Comuneros III 1,068 596 6%)
15. Local del Norte I 1,040 560 3%)
16. ESE Giron I 362 202 (55%)
Cucuta (Eastern) 17. Hospital Erasmo Meoz III 3,653 1,124 (30.7%)
Florencia Amazonian) 18. Clı ´nica Medilaser III 1,105 510 (46.1%)
Riohacha (Caribbean) 19. Hospital Nuestra Sen ˜ora de los Remedios III 2,603 801 (30.7%)
doi:10.1371/journal.pntd.0001195.t001
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was performed following recommendations of the manufacturer
and a result $5 points was considered positive.
Neither obligation nor official recommendation exists in
Colombia to perform serological screening for toxoplasmosis
during pregnancy, but some gynecologists request the mothers do
this. Particularly, in Quindio region some health insurance
companies and the health bureau of the city pay for the cost for
serological diagnosis of this infection in pregnant women from
patients of the lowest socioeconomic levels (SISBEN 0, 1 and 2).
For this reason, another criterion for postnatal follow up of the
children was the mother’s history of diagnosis or treatment during
pregnancy for toxoplasmosis. This information was collected in the
questionnaire used for this study at the moment of delivery at the
hospital or maternal-child health service. Parents of these children
were also invited to have their child followed clinically and
serologically for congenital toxoplasmosis. Also, pediatricians
participating in the study referred for confirmation, at the national
reference laboratory, serum samples from cases with umbilical
cord blood sample negative but that they considered presented
compatible signs (hydrocephaly, cataracts or cerebral calcifica-
tions).
Complementary assessment of mother and infant
Children who had confirmed positive results on neonatal
screening for anti-Toxoplasma IgM or IgA or past history of
treatment of toxoplasmosis during pregnancy or compatible signs
were invited for diagnostic confirmation. Written, informed
consent for additional assessment and follow-up was obtained
from the guardians responsible for those children who tested
positive. In each city there was a research assistant for the project
that recalled mothers and children with criteria for follow up. Each
child was examined by a neonatologist in each city, and if
ophthalmological symptoms were present the child was referred to
ophthalmologist. Additionally, a cerebral tomography was also
indicated if physical examination was abnormal. If physical
examination was normal, the children were recalled to obtain
additional blood samples each month. Peripheral blood was
collected from the mothers and their infants for confirmatory
serological tests. During follow up mother and child were tested
first for specific anti-Toxoplasma IgG, IgM, IgA and western blot
and then only the child’s sample was tested for IgG, IgM and IgA.
Sera obtained from the child and mother was tested using an
enzyme immune- assay for the quantitative detection of anti-
Toxoplasma IgM by two different commercial test (Vircell, Spain
and Human, Germany) and for IgA antibodies by ISAGA
(Biomerieux, Lyon, France) according to the manufacturer’s
instructions. Samples showing optical densities higher than the
cut-off provided by the manufacturer were considered positive for
ELISA assays and if $5 points for ISAGA IgA test. Maternal and
infant serum samples were also submitted to western blot to
compare immunological profiles of anti-Toxoplasma IgG and IgM.
Consequent to any alteration identified during the initial clinical
assessment, the children were tested for complete blood count,
cerebrospinal fluid analysis and ophthalmologic assessment. All
samples from mother and child were referred to the ‘‘Centro de
Investigaciones Biome ´dicas’’ at the University of Quindio.
All infants identified by neonatal screening were followed up
until their infection status had been established. A diagnosis of
congenital toxoplasmosis was confirmed, as described by the
european network on congenital toxoplasmosis [24]. Confirmation
of diagnosis was made on the basis of persistence of specific IgG
antibodies beyond 12 months of age or by the presence of stable
titers in absence of treatment or by the presence of compatible
symptoms (cerebral calcifications, retinochoroiditis or hydroceph-
aly) and a specific anti-Toxoplasma IgG and IgM positive test in
mother and of anti-Toxoplasma IgG antibodies in child serum [24].
Children with decreasing IgG titers and who became anti-
Toxoplasma IgG negative in absence of treatment were considered
to be non-infected. Treatment was provided based on current
recommendations [9] with sulphadiazine, pyrimethamine, and
folinic acid.
Geographical factors analysis
We analyzed the differences in incidence of markers for
congenital toxoplasmosis between cities by comparing geograph-
ical factors such as the altitude (meters above sea), mean annual
temperature of the localities in Celsius degrees and the mean
annual rainfall in mm
3. This data were obtained from the 2008
annual report of the IDEAM (official Colombian institute for
hydrological and meteorological information) [25].
Data analysis
Calculations were performed using the Epi-Info 6 (CDC,
Atlanta, GA, USA, November 1993), EpiDat 3.1 (Xunta de
Galicia, Spain and OPS, Spain) and SPSS versio ´n 14 (SPSS Inc.
Chicago, USA) statistical programs. Results are expressed as the
mean and standard deviation for continuous variables and N (%)
for categorical variables. Correlation analyses were done by
Pearson’s test. Chi square test was applied to evaluate the
differences in the percent of markers for congenital toxoplasmosis
between cities. Epi-Info was used to perform stratified- analysis
(Centers for Disease Control and Prevention [http://www.cdc.
gov/epiinfo/]). Values below p,0.05 were considered statistically
significant.
Results
Characteristics of the sample and hospitals and centers
The newborns studied (15,333) accounts for 2.7% of the
553,912 live newborns delivered in 2009 in Colombia and for the
9.1% of births in the seven cities included in this study, N: 167,566
(Figure 1). The size of the sample related to the total of births
during 2009, by each hospital or center, and the referral level is
depicted in Table 1. Only 300 samples in Barranquilla (Hospital
Universidad del Norte) and 400 in Bogota (Hospital Engativa)
were collected during the first five months of 2010. The 47% (n: 9)
of the participating hospitals were from the third level, 31% (n: 6)
from the second level and 21% (n: 4) from the first level of referral.
The 96.5% of the newborns were from hospitals and maternal-
child services that received patients of the levels 0 to 2, which are
the lowest levels of SISBEN (Table S1). Only 3.5% (n: 544) of the
sample was from one hospital with a majority of population with
levels of SISBEN greater than 3 (Clinica Colombia in Bogota).
Frequency of anti-Toxoplasma IgM and IgA antibodies in
umbilical cord blood samples
In the regional laboratories 118 umbilical cord blood samples
were positive for anti-Toxoplasma IgM ELISA assay, but then only
61 (51.7%) were confirmed by the western blot and retesting at the
reference laboratory. Consequently the prevalence for confirmed
specific IgM was of 0.39%. Nine samples of 1,613 tested were
positives for ISAGA IgA assay (0.5%). Results by hospital or
maternal child health care center and city are shown in Table 2.
The rate of confirmed positive anti-Toxoplasma IgM test in cord
blood samples by grouping hospitals and centers by city was:
Bogota 0.2% (Central region); Bucaramanga 0.23% and Cucuta
0% (Eastern region), Barranquilla 0.06% and Riohacha 0%
Colombian Newborn Screening for Toxoplasmosis
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1.8% (Amazonia). For specific IgA anti-Toxoplasma we found:
Bogota ´ 0.39%; Bucaramanga 0.78%; Barranquilla 1.2%, Armenia
0%, Cucuta 0%, Florencia 0% and Riohacha 0%.
Frequency of history of toxoplasmosis during pregnancy
and children with compatible signs
A history of diagnosis for toxoplasmosis during pregnancy was
found in 143 questionnaires and from these mothers, 82 received
antibiotics (79 spiramycin, and three pyrimethamine- sulfadoxine
combination). From these mothers only two children whose
mothers were treated (one with pyrimethamine-sulfadoxine during
two months and one with spiramycin during three months) had
anti-Toxoplasma IgM test positive in umbilical cord blood, however
in the follow up both children become negative.
Five samples of serum from children who were negative at the
umbilical cord blood tests (four from Bogota and one from
Barranquilla) were referred because the newborn presented
clinical signs compatible with congenital toxoplasmosis (hydro-
cephaly, cerebral calcifications or cataracts). In these cases mothers
did not have history of toxoplasmosis during pregnancy and they
did not received treatment during pregnancy.
Frequency of confirmed and symptomatic congenital
infection
We found and followed 109 of the 218 children that had some
of the criteria for postnatal confirmatory tests (Figure 2). We
confirmed a congenital toxoplasmosis infection in 15 children: 7
were symptomatic, and three of them died before the first month
of life. Eight infected children were identified by a positive specific
IgM test in umbilical cord blood sample, one by a positive specific
IgA test in umbilical cord blood, five by the past history of
treatment during pregnancy and one by compatible symptoms. A
summary of the clinical characteristics, criteria for recruitment and
for diagnosis is showed in Table 3.
In newborns of mothers with history of diagnosis or treatment for
toxoplasmosis during pregnancy, 56 children could be followed and
five were confirmed as congenitally infected (8.9%). During
pregnancy, two mothers of the confirmed congenitally infected
children were treated with spiramycin and one with pyrimethamine-
sulfadoxine combination, and children were asymptomatic. The
other two children did not received prenatal treatment, one of them
died during the first week of life and another had splenomegaly.
One child who was referred because he was presenting
compatible signs for congenital toxoplasmosis, had specific anti-
Toxoplasma IgA test positive in peripheral blood five months after
birth, that confirmed congenital toxoplasmosis. The child was not
treated prenatally and had choriorretinitis.
In the postnatal confirmatory samples, seven children had a
specific anti-Toxoplasma IgM positive test and six children had a
specific anti-Toxoplasma IgA positive test. Between the seven
children with specific IgM positive, four of them also had specific
IgA. Two children with specific IgA positive test did not have
specific IgM.
Three of 15 children (20%) with confirmed congenital
toxoplasmosis died during the first month of life: one in
Barranquilla and other two in Florencia. The mothers of these
three children had positive tests for anti-Toxoplasma IgG and IgM.
In the three cases there was no suspicion of toxoplasmosis by
pediatricians that attended the cases. Cerebral tomography of one
of the cases in Florencia is shown on Figure S1. In this particular
case, the cell culture from cerebral spinal fluid showed growth of
Toxoplasma tachyzoites, confirmed by direct immunofluorescence
assay. In contrast, three prenatally treated children were
asymptomatic. The lethality rate in 12 prenatally untreated
children for this newborn congenital toxoplasmosis screening
program was of 25%.
Geographical factors influencing frequency of serological
markers for congenital toxoplasmosis
Incidence of specific anti-Toxoplasma IgM in umbilical blood
cord (p=.000) and of the percent of mothers with history of
toxoplasmosis during pregnancy (p: 0.000), were significantly
different between cities, but not the incidence of specific IgA (p:
0.22). As the study involved different type of institutions, we
analyzed the influence of socioeconomics classification, referral
Figure 1. Geographical distribution and sample percent of the births. Colombian multicentric newborn screening for congenital
toxoplasmosis.
doi:10.1371/journal.pntd.0001195.g001
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for congenital toxoplasmosis: incidence of anti-Toxoplasma IgM or
IgA in umbilical cord or frequency of history of toxoplasmosis
during pregnancy (Table 4).
Pearson correlation test showed that neither referral level nor
socioeconomics index was correlated with the incidence of markers
for congenital toxoplasmosis. Concerning the geographical factors,
altitude or average temperature of the city were not correlated
with the incidence of markers, but the mean annual rain fall was
significantly correlated to differences in the frequency of
serological markers for congenital toxoplasmosis in each city
(Table 5).
Table 2. Frequency of markers for congenital toxoplasmosis in hospitals and maternal child care centers in 7 cities.
City
Toxoplasmosis history
during pregnancy IgM umbilical cord blood IgA umbilical cord blood
Hospitals or maternal child
centers
Armenia 27/753 (3.5%) 6/753 (0.79%) 0/75 (0%) 1. Hospital San Juan de Dios
35/568 (6.1%) 19/568 (3.3%) 0/57 (0%) 2. Hospital La Misericordia
5/196 (2.5%) 6/196 (3.0%) 0/19 (0%) 3. Hospital del Sur
Total in Armenia 64/1517
(4.2% IC95% 3.4–5.3)
31/1517
(2.0% IC95%1.3–2.8)
0/151
(0% IC95% 0–2.4)
Total markers: 6.2%
Barranquilla 6/1043 (0.5%) 1/1043 (0.09%) 0/104 (0%) 4. H. Universidad del Norte
7/688 (1.0%) 0/688 (0%) 1/95 (1.0%) 5. Hospital Santa Mo ´nica
4/1170 (0.3%) 1/1170 (0.8%) 3/117 (2.5%) 6. Hospital Nin ˜oJ e ´sus
Total in Barranquilla 17/2901
(0.58% IC95% 0.5–1.3)
2/2901
(0.06% IC95% 0–.2)
4/316
(1.2% IC95% 0.3–3.3)
7. Total markers:1.8%
Bogota 5/544 (0.9%) 4/544 (0.73%) 0/54 (0%) 8. Clı ´nica Colombia
15/1971 (0.76%) 2/1971 (0.1%) 1/191 (0.52%) 9. Engativa
0/301 (0%) 0/301 (0%) 0/30 (0%) 10. La Victoria
2/545 (0.36%) 1/545 (0.18%) 0/28 (0%) 11. Simon Bolivar
14/2037 (0.68%) 5/2037 (0.24%) 1/203 (0.49%) 12. Instituto Materno Infantil
Total in Bogota 36/5398
(0.66% IC95% 0.4–0.8)
12/5398
(0.2% IC95% 0.08–0.3)
2/506
(0.39% IC95%0.04–1.4)
13. Total markers: 1.2%
Bucaramanga 2/1.019 (0.19%) 1/1.019 (0.09%) 1/141 (0.7%) 14. Hospital de Floridablanca
0/659 (0%) 2/659 (0.3%) 1/76 (1.3%) 15. UIMIST
7/596 (1.1%) 1/596 (0.16%) 0/69 (0%) 16. Los Comuneros
0/560 (0%) 3/560 (0.53%) 1/66 (1.5%) 17. Local del Norte
1/202 (0.49%) 0/202 (0%) 0/30 (0%) 18. ESE Giron
Total in Bucaramanga 10/3036
(0.32% IC95%0.1–0.5)
7/3036
(0.23% IC95%0.04–0.4)
3/382
(0.78% IC95%0.1–2.2)
19. Total markers: 1.3%
Cucuta 6/1124 (0.53% IC95% 0.06–1) 0/1124 (0% IC95% 0–0.3) 0/110 (0% IC95% 0–3.2) 20. Hospital Erasmo Meoz; Total
markers: 0.5%
Florencia 4/510 (0.78% IC95% 0.2–1.9) 9/510 (1.8% IC95% 0.5–3) 0/56 (0% IC95% 0–6.3) 21. Clı ´nica Medilaser; Total
markers: 3.1%
Riohacha 6/801 (0.74% IC95% 0.09–1.4) 0/801 (0% IC95% 0–0.4) 0/92 (0% IC95% 0–3.9) 22. Nuestra Sen ˜ora de los
Remedios; Total markers: 0.7%
doi:10.1371/journal.pntd.0001195.t002
Figure 2. Flowchart and results of the postnatal confirmatory tests at the follow up.
doi:10.1371/journal.pntd.0001195.g002
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Initials-(City) Signs or symptoms?
Diagnostic criteria after
day 10 of life
Index IgM umbilical
cord blood sample Criteria for following
1. SDG (Armenia) Asymptomatic IgG, IgM and IgA positives in child 9,8 IgM+umbilical cord
2. JE (Armenia) Asymptomatic IgG and IgM positives in child 12,3 IgM+umbilical cord
3. SR (Armenia) Asymptomatic IgG, IgM and IgA positives in child 19,9 IgM+umbilical cord
4. AM (Bogota ´) Choriorretinitis and cerebral
calcifications
IgG and IgA positives in child
in month five of life
0 Compatible signs
5. SM (Bogota ´) Splenomegaly Stable titers IgG, IgA+ 0I g M +mother
6. PAC (Florencia) Preterm, calcifications,
death after 3 weeks of life
IgG and IgM positives in child 13,2 IgM+umbilical cord
7. MH (Bucaramanga) Neurological soft signs,
cerebral tomography normal
IgG, IgM and IgA positives in child 12 IgM+umbilical cord
8. YB (Barranquilla Preterm, choriorretinitis,
cerebral calcifications
IgG e IgM positives in child 0,6 IgA+umbilical cord
9. LP (Barranquilla) Asymptomatic IgG, IgM and IgA positives in child 11 IgM+umbilical cord
10. ZCs (Bogota) Asymptomatic IgG positive after month 12 2,2 IgM+mother and 6 months of
treatment with spyramicin
during pregnancy
11. AM (Bogota) Asymptomatic IgG positive after month 12 8,8 IgM+mother and 2 months of
treatment with spyramicin
during pregnancy
12. YR (Bogota Asymptomatic IgG positive after first year of
life, IgG stable titers
9,8 IgM+umbilical cord
13. OA (Barranquilla) Hydrocephaly, cerebral
calcifications, choriorretinitis,
death at first week of life
Compatible symptoms, mother
was IgM positive in pregnancy
4,1 IgM+mother
14. ANS (Florencia) Respiratory distress syndrome,
death after three weeks of life
Compatible symptoms, mother
was IgM and IgA positives
10,4 IgM+umbilical cord
15. JPM (Armenia) Asymptomatic PCR amniotic fluid positive,
IgG stable titers
2,2 IgM+mother and treatment
during pregnancy
doi:10.1371/journal.pntd.0001195.t003
Table 4. Rate of markers for congenital toxoplasmosis and geographical characteristics.
City (size of the sample,
number of hospitals and
centers)
% markers for congenital
toxoplasmosis
Altitude above
sea -meters-
Average
temperature 6C
Mean annual precipitation
mm
3
Florencia
(n: 510, one hospital)
3.1 242 30 3,840
Armenia
(n: 1.563, two hospitals, one
center)
6.2 1,551 26 2,500
Barranquilla
(n: 2.901, three hospitals)
1.8 0 27 821
Bogota
(n: 5.398, five hospitals)
1.2 2,642 12 995
Bucaramanga
(n: 3.036, four hospitals, one
center)
1.3 960 24 1,279
Cucuta
(n: 1.124; one hospital)
0.5 320 28 806
Riohacha
(n: 801; one hospital)
0.7 52 28 48
doi:10.1371/journal.pntd.0001195.t004
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This is the first multicentric study in Colombia of congenital
toxoplasmosis incidence. As the selection of the sample was on the basis
of voluntary acceptation to participate, the sample is representative
only for the centers involved in the study. However, they should
provide representative data for the incidence in the city where they
were obtained. Incidence in toxoplasmosis could differ by the
socioeconomics, age or geographical factors [26] but in present study
these variables not determined the differences in incidence of
congenital toxoplasmosis between cities. Thus, the incidence of
markers indicates a similar situation to the described in Brazil [27].
The findings suggest epidemiological differences in infection in distinct
localities. Our methods are not influenced by inclusion of cases or more
sensitive methods because cases were recruited by the same criteria
( e v e r yc h i l db o r na te a c hh o s p i t a lo rc e n t e rd u r i n gt h ep e r i o do fs a m p l e
collection), test were free of costs for parents, no refusal was recorded
from their parents, laboratories performed the same assays, personnel
received the same training and all positive samples were confirmed at
the referral center by the same methodology.
This study found three children that died before first month of
life as a consequence of the congenital toxoplasmosis. In previous
reports, of newborn screening, mortality cases between congeni-
tally infected children were also described: one between 19
newborns in the study in Poland [14] and one case between 20
newborns in Porto Alegro’s study [15]. Although our rate of
mortality seems higher, it is difficult to conclude about the real
magnitude of the problem due to the high number of children loss
of follow up. Future studies should focus in to obtaining a complete
follow up of all of the cases, but it is clear that congenital
toxoplasmosis is an important cause of children early mortality in
Colombia.
We did an aggregation of the three markers because each one
independently indicates the risk for congenital toxoplasmosis.
Thus, anti-Toxoplasma IgA marker was obtained in the anti-
Toxoplasma IgM negative sample and history of toxoplasmosis
during pregnancy identified children without specific IgM or IgA
in umbilical cord sample. For these reasons we considered that
complete evaluation of the risk for congenital toxoplasmosis
cannot be attained without considering other factors besides the
presence of specific IgM in umbilical cord blood. This seems
critical for cities as Barranquilla and Bucaramanga which had very
low incidence of IgM but the highest incidence of positive IgA.
Therefore it is not possible to say that congenital toxoplasmosis
Table 5. Pearson test for correlations at the Colombian multicentric newborn screening for congenital toxoplasmosis.
Referral level
of the center
Altitudes
(meters
above sea)
Average
temperature
of the city 6C
Mean rainfall
mm
3
SISBEN
level $3
Mean age
years of the
mother
Incidence markers
(IgM and IgA
umbilical cord and
past history during
pregnancy)
Referall level
of the center
Pearson Correlation 1 0.128 20.219 20.100 0.282 0.575(*) 20.257
Sig. (2-tailed) 0.601 0.368 0.685 0.273 0.016 0.287
N 1 9 1 91 9 1 9 1 71 7 1 9
Altitude Pearson Correlation 0.128 1 20.907(**) 0.014 0.568(*) 0.050 20.007
Sig. (2-tailed) 0.601 0.000 0.955 0.017 0.848 0.978
N 1 9 1 91 9 1 9 1 71 7 1 9
Average
Temperature
Pearson Correlation 20.219 20.907(**) 1 0.307 20.694(**) 20.305 0.342
Sig. (2-tailed) 0.368 0.000 0.201 0.002 0.234 0.152
N 1 9 1 91 9 1 9 1 71 7 1 9
Mean
rainfall mm
3
Pearson Correlation 20.100 0.014 0.307 1 20.110 20.267 0.612(**)
Sig. (2-tailed) 0.685 0.955 0.201 0.675 0.300 0.005
N 1 9 1 91 9 1 9 1 71 7 1 9
SISBEN
level $3
Pearson Correlation 0.282 0.568(*) 20.694(**) 20.110 1 0.785(**) 20.185
Sig. (2-tailed) 0.273 0.017 0.002 0.675 0.000 0.477
N 1 7 1 71 7 1 7 1 71 7 1 7
Mean age in
years
of the mother
Pearson Correlation 0.575(*) 0.050 20.305 20.267 0.785(**) 1 20.367
Sig. (2-tailed) 0.016 0.848 0.234 0.300 0.000 0.148
N 1 7 1 71 7 1 7 1 71 7 1 7
Incidence of
markers
Pearson Correlation 20.257 20.007 0.342 0.612(**) 20.185 20.367 1
Sig. (2-tailed) 0.287 0.978 0.152 0.005 0.477 0.148
N 1 9 1 91 9 1 9 1 71 7 1 9
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
doi:10.1371/journal.pntd.0001195.t005
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Furthermore, in cities such as Cucuta and Riohacha all three
markers were very low, being consistent with this assumption.
Previous studies in others countries have targeted the frequency
of IgM or IgA in umbilical cord as markers for congenital
infection, however as some mothers received treatment and this
can influence the presence of serological markers at birth in
congenitally infected children [28], we included into the analysis
the history of diagnosis and treatment for toxoplasmosis during
pregnancy. The results of incidence of anti-Toxoplasma IgM in
umbilical cord blood samples and of the percentage of mothers
with history of diagnosis or treatment during pregnancy were
correlated, so cities with hospitals and centers with high incidence
of mothers with history of toxoplasmosis during pregnancy also
had high incidence of IgM in umbilical cord blood sample. In
contrast, the incidence of IgA was not correlated with these
markers. Anti- Toxoplasma IgA positive test in newborns was high
in cities where anti-Toxoplasma IgM in cord blood was low. In cities
where hospitals and centers had a high incidence of IgM, the anti-
Toxoplasma IgA in umbilical cord blood it was not found
exclusively.
Anti-Toxoplasma IgA can be found alone without anti-Toxoplasma
IgM. In present study, two children with confirmed congenital
infection had IgA as the only diagnostic marker of congenital
infection after day ten of life. A possible explanation for the
differences in the incidence of anti-Toxoplasma IgA between cities
are the consumption of the IgM production before birth in
infections acquired early during pregnancy [13,23,28]. Therefore
in these cities the pattern of acquisition can differ and infections
can occur earlier than in other cities. Other alternative
explanation is genetic differences in the population to produce
IgA or differences in the Toxoplasma strains between cities. It
should be also noted that IgM is more often negative in the
symptomatic infants, because of the earlier infection in fetal life. In
asymptomatic patients, the frequency of positive IgM is much
higher [13,23,28].
The factors associated to the incidence of each positive
marker independently or altogether did not correlate to the level
of SISBEN or to the level of referral of the center. Looking for
geographical links between cities with hospitals and centers with
high or low incidence of markers for congenital toxoplasmosis,
we analyzed the altitude, the mean temperature and the mean
annual rainfall. We found that mean annual rainfall was
strongly related to the level of incidence of markers for
congenital toxoplasmosis. The association with this geographical
parameter is not surprising; the first studies about survival of
sporulated Toxoplasma gondii oocysts in water and soil indicated
that humidity is a critical parameter for their infectivity [29,30].
In France, a study about the incidence risk in cats was related to
mean precipitation, explaining both the spatial and temporal
variability in risk: local conditions explained differences between
the study sites and incidence risk increased during rainy years
[31].
One advantage of the present study design is that the
occurrence of congenital toxoplasmosis in infants identified by
neonatal screening was confirmed using a criteria that is
considered to be a true indicator of the presence or absence
of the disease [24], but that h a sb e e na p p l i e di no n l yf e w
previous studies. The confirmation of the results in the umbilical
cord sample indicated that the test we use was few specific in a
similar manner to the reported with the fluorescence based
assay in Brazil. In present study, 51.6% of the initially positive
neonatal screening results were false-positive. Other investiga-
tors, using IgM fluorometric assay reported 61.5% [17], 78.6%
[32] and 91% [15] false-positive results. A high proportion of
false-positive results are generally accepted for screening tests,
especially in the case of populations with low incidence of the
disease.
n summary, the first Colombian multicentric study identified
symptomatic and asymptomatic congenital infected children and a
high lethality rate in prenatally untreated children (25%) in
hospitals and centers from different level of referral in five of seven
cities participating at the study. This program identified nine
children otherwise undiagnosed (no previous history in mother or
no clinical suspicion). For the first time a significant correlation
was identified between mean rainfall at the city and the incidence
of markers for congenital infection. In Colombia, each city or
region should define the necessity of newborn screening for
congenital toxoplasmosis according to local studies.
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